Creating treatments for Marburg virus infections
Official title: Development of Therapeutic Products for Marburg Virus
Funded at Abvacc, INC. · NIH-10787970 · Data updated 2026-11-12
This study is working on a new treatment for Marburg virus infections, which can be very serious, and aims to create a safe and effective option to help patients who are affected by this illness.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Abvacc, INC. NIH-funded |
| Lab location | 1 site (Rockville, United States) |
| Project start | May 17, 2021 |
| Project end | December 16, 2025 |
| Funding year | 2023 |
| Award (this year) | $1,696,004 |
| NIH project number | 75N93021C00021-P00003-9999-1 |
| Project ID | NIH-10787970 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who are at risk of or have been diagnosed with Marburg virus infections.
✕Less likely to help
Patients with other viral infections or those not at risk for Marburg virus will likely not benefit from this research.
What this research studies
This research focuses on developing a new therapeutic product aimed at treating infections caused by the Marburg virus, which is a serious emerging infectious disease. The project involves several stages, including optimizing the chemistry of the therapeutic candidate, ensuring it can be manufactured safely and effectively, and conducting preclinical tests to assess its safety and efficacy. Patients may benefit from this research as it aims to provide a viable treatment option for a currently severe and often fatal viral infection.
Why it matters
Potential benefit: If successful, this research could lead to effective treatments for patients infected with the Marburg virus, potentially saving lives.
How similar studies have gone: While research on Marburg virus treatments is limited, similar approaches for other emerging infectious diseases have shown promise in developing effective therapies.
Where this research is happening
-
Abvacc, INC.
Rockville, United States Active
Researchers
- Principal investigator: Aman, M Javad — Abvacc, INC.
- Study coordinator: Aman, M Javad
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.